| Zugriffe | |
|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 468 |
| Januar 2025 | Februar 2025 | März 2025 | April 2025 | Mai 2025 | Juni 2025 | Juli 2025 | |
|---|---|---|---|---|---|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 1 | 17 | 8 | 4 | 1 | 8 | 0 |
| Zugriffe | |
|---|---|
| diss_f.niehr.pdf | 251 |
